Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Checkpoint Therapeutics Inc

Current price
1.79 USD -0.11 USD (-5.79%)
Last closed 1.84 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 68 541 560 USD
Yield for 12 month -32.71 %
21.11.2021 - 28.11.2021

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Address: 95 Sawyer Road, Waltham, MA, United States, 02453

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

17.25 USD

P/E ratio

Dividend Yield

Current Year

+103 000 USD

Last Year

+192 000 USD

Current Quarter

Last Quarter

+6 000 USD

Current Year

-43 463 000 USD

Last Year

-49 633 000 USD

Current Quarter

Last Quarter

-8 292 999 USD

Key Figures CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Operating Margin TTM -66195.59 %
PE Ratio
Return On Assets TTM -314.85 %
PEG Ratio
Return On Equity TTM -1220.38 %
Wall Street Target Price 17.25 USD
Revenue TTM 68 000 USD
Book Value -0.29 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -91.9 %
Dividend Yield
Gross Profit TTM -48 185 000 USD
Earnings per share -2.61 USD
Diluted Eps TTM -2.61 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CKPT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 06.12.2022
Dividend Date

Stock Valuation CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 568.8697
Price Sales TTM 616.7147
Enterprise Value EBITDA -1.1236
Price Book MRQ 8.5555

Financials CKPT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CKPT

For 52 weeks

1.3 USD 3.62 USD
50 Day MA 1.73 USD
Shares Short Prior Month 3 521 074
200 Day MA 1.98 USD
Short Ratio 10.43
Shares Short 3 968 810
Short Percent 11.87 %

Dynamics of changes in the value of assets




430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds



14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics